|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC43 |
Gene summary for CCDC43 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC43 | Gene ID | 124808 |
| Gene name | coiled-coil domain containing 43 | |
| Gene Alias | CCDC43 | |
| Cytomap | 17q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q96MW1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 124808 | CCDC43 | LZE2T | Human | Esophagus | ESCC | 2.53e-04 | 5.16e-01 | 0.082 |
| 124808 | CCDC43 | LZE4T | Human | Esophagus | ESCC | 2.18e-13 | 4.84e-01 | 0.0811 |
| 124808 | CCDC43 | LZE7T | Human | Esophagus | ESCC | 1.96e-10 | 4.15e-01 | 0.0667 |
| 124808 | CCDC43 | LZE24T | Human | Esophagus | ESCC | 1.98e-15 | 4.93e-01 | 0.0596 |
| 124808 | CCDC43 | LZE6T | Human | Esophagus | ESCC | 1.48e-05 | 3.08e-01 | 0.0845 |
| 124808 | CCDC43 | P1T-E | Human | Esophagus | ESCC | 8.26e-06 | 3.19e-01 | 0.0875 |
| 124808 | CCDC43 | P2T-E | Human | Esophagus | ESCC | 7.02e-30 | 5.34e-01 | 0.1177 |
| 124808 | CCDC43 | P4T-E | Human | Esophagus | ESCC | 1.64e-29 | 6.63e-01 | 0.1323 |
| 124808 | CCDC43 | P5T-E | Human | Esophagus | ESCC | 1.10e-33 | 7.48e-01 | 0.1327 |
| 124808 | CCDC43 | P8T-E | Human | Esophagus | ESCC | 1.15e-21 | 4.68e-01 | 0.0889 |
| 124808 | CCDC43 | P9T-E | Human | Esophagus | ESCC | 7.12e-15 | 3.78e-01 | 0.1131 |
| 124808 | CCDC43 | P10T-E | Human | Esophagus | ESCC | 1.30e-13 | 2.44e-01 | 0.116 |
| 124808 | CCDC43 | P11T-E | Human | Esophagus | ESCC | 2.00e-13 | 6.38e-01 | 0.1426 |
| 124808 | CCDC43 | P12T-E | Human | Esophagus | ESCC | 1.43e-29 | 6.16e-01 | 0.1122 |
| 124808 | CCDC43 | P15T-E | Human | Esophagus | ESCC | 8.47e-35 | 6.40e-01 | 0.1149 |
| 124808 | CCDC43 | P16T-E | Human | Esophagus | ESCC | 1.25e-26 | 5.01e-01 | 0.1153 |
| 124808 | CCDC43 | P17T-E | Human | Esophagus | ESCC | 6.35e-12 | 3.69e-01 | 0.1278 |
| 124808 | CCDC43 | P19T-E | Human | Esophagus | ESCC | 3.39e-07 | 6.75e-01 | 0.1662 |
| 124808 | CCDC43 | P20T-E | Human | Esophagus | ESCC | 4.96e-12 | 2.90e-01 | 0.1124 |
| 124808 | CCDC43 | P21T-E | Human | Esophagus | ESCC | 2.31e-23 | 4.85e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC43 | SNV | Missense_Mutation | novel | c.305N>A | p.Ala102Asp | p.A102D | Q96MW1 | protein_coding | deleterious(0) | possibly_damaging(0.801) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| CCDC43 | SNV | Missense_Mutation | c.184N>A | p.Gly62Arg | p.G62R | Q96MW1 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-D8-A1JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CCDC43 | SNV | Missense_Mutation | rs754010368 | c.530N>A | p.Arg177Gln | p.R177Q | Q96MW1 | protein_coding | tolerated(0.41) | benign(0.023) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CCDC43 | SNV | Missense_Mutation | rs778956757 | c.665N>A | p.Arg222Gln | p.R222Q | Q96MW1 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC43 | SNV | Missense_Mutation | rs148980983 | c.248N>A | p.Arg83Gln | p.R83Q | Q96MW1 | protein_coding | tolerated(0.32) | benign(0.04) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC43 | SNV | Missense_Mutation | novel | c.194N>A | p.Ser65Tyr | p.S65Y | Q96MW1 | protein_coding | deleterious(0) | possibly_damaging(0.742) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC43 | SNV | Missense_Mutation | novel | c.433N>T | p.Ala145Ser | p.A145S | Q96MW1 | protein_coding | tolerated(0.16) | benign(0.053) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC43 | SNV | Missense_Mutation | c.162A>C | p.Glu54Asp | p.E54D | Q96MW1 | protein_coding | tolerated(0.35) | benign(0.019) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| CCDC43 | SNV | Missense_Mutation | c.303N>T | p.Gln101His | p.Q101H | Q96MW1 | protein_coding | deleterious(0.01) | possibly_damaging(0.562) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC43 | SNV | Missense_Mutation | novel | c.230G>A | p.Cys77Tyr | p.C77Y | Q96MW1 | protein_coding | deleterious(0.03) | possibly_damaging(0.511) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |